KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Idexx Laboratories (IDXX) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for Idexx Laboratories (IDXX) over the last 17 years, with Q3 2025 value amounting to $85000.0.

  • Idexx Laboratories' Gains from Investment Securities fell 6100.92% to $85000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $7.2 million, marking a year-over-year decrease of 3155.2%. This contributed to the annual value of $10.5 million for FY2024, which is 557.39% up from last year.
  • Per Idexx Laboratories' latest filing, its Gains from Investment Securities stood at $85000.0 for Q3 2025, which was down 6100.92% from $970000.0 recorded in Q2 2025.
  • In the past 5 years, Idexx Laboratories' Gains from Investment Securities ranged from a high of $15.0 million in Q1 2021 and a low of -$31000.0 during Q2 2021
  • In the last 5 years, Idexx Laboratories' Gains from Investment Securities had a median value of $162000.0 in 2022 and averaged $2.8 million.
  • Its Gains from Investment Securities has fluctuated over the past 5 years, first plummeted by 14843.75% in 2021, then surged by 112784.81% in 2025.
  • Quarter analysis of 5 years shows Idexx Laboratories' Gains from Investment Securities stood at $61000.0 in 2021, then decreased by 11.48% to $54000.0 in 2022, then increased by 25.93% to $68000.0 in 2023, then crashed by 33.82% to $45000.0 in 2024, then soared by 88.89% to $85000.0 in 2025.
  • Its Gains from Investment Securities was $85000.0 in Q3 2025, compared to $970000.0 in Q2 2025 and $6.1 million in Q1 2025.